Bexsero

Adult Dosing .

Dosage forms:  INJ

Special Note

[formulation clarification]

Info: not interchangeable w/ meningococcal group B vaccine (recombinant) (MenB-FHbp); if doses from different MenB products used, then series must be restarted w/ one product

invasive meningococcal dz prevention

[18-25 yo, pts w/ low infection risk]

Dose: 0.5 mL IM x1 at mo 0 and mo 6 for 2 total doses; Info: for healthy pts 16-23 yo based on shared clinical decision-making, preferred in pts 16-18 yo; if 2nd dose given <6mo after 1st dose, give 3rd dose at least 4mo after 2nd dose; search 'immunization' for epocrates Adult Immunization decision tool incl. links to CDC/ACIP schedules

[18-25 yo, pts w/ high infection risk]

Dose: 0.5 mL IM x1 at mo 0, mo 1-2, and mo 6 for 3 total doses; Info: for pts w/ asplenia, persistent complement component deficiency, pts on complement inhibitor tx, lab workers exposed to N. meningitidis; if 2nd dose given at least 6mo after 1st dose, 3rd dose not needed; if 3rd dose given <4mo after 2nd dose, give 4th dose at least 4mo after 3rd dose; give booster 1y after primary series, then q2-3y if continued risk; search 'immunization' for epocrates Adult Immunization decision tool incl. links to CDC/ACIP schedules

[26 yo and older, pts w/ high infection risk (off-label)]

Dose: 0.5 mL IM x1 at mo 0, mo 1-2, and mo 6 for 3 total doses; Info: for pts w/ asplenia, persistent complement component deficiency, pts on complement inhibitor tx, lab workers exposed to N. meningitidis; if 2nd dose given at least 6mo after 1st dose, 3rd dose not needed; if 3rd dose given <4mo after 2nd dose, give 4th dose at least 4mo after 3rd dose; give booster 1y after primary series, then q2-3y if continued risk; search 'immunization' for epocrates Adult Immunization decision tool incl. links to CDC/ACIP schedules

renal dosing

[no adjustment]

renal impairment: no adjustment

HD/PD: no adjustment; no supplement

hepatic dosing

[no adjustment]

Peds Dosing .

Dosage forms:  INJ

Special Note

[formulation clarification]

Info: not interchangeable w/ meningococcal group B vaccine (recombinant) (MenB-FHbp); if doses from different MenB products used, then series must be restarted w/ one product

invasive meningococcal dz prevention

[10-17 yo, pts w/ low infection risk]

Dose: 0.5 mL IM x1 at mo 0 and mo 6 for 2 total doses; Info: for healthy pts 16-23 yo based on shared clinical decision-making, preferred in pts 16-18 yo; if 2nd dose given <6mo after 1st dose, give 3rd dose at least 4mo after 2nd dose; search 'immunization' for epocrates Child/Adolescent Immunization decision tool incl. links to CDC/ACIP schedules

[10-17 yo, pts w/ high infection risk]

Dose: 0.5 mL IM x1 at mo 0, mo 1-2, and mo 6 for 3 total doses; Info: for pts w/ asplenia, persistent complement component deficiency, pts on complement inhibitor tx; if 2nd dose given at least 6mo after 1st dose, 3rd dose not needed; if 3rd dose given <4mo after 2nd dose, give 4th dose at least 4mo after 3rd dose; give booster 1y after primary series, then q2-3y if continued risk; search 'immunization' for epocrates Child/Adolescent Immunization decision tool incl. links to CDC/ACIP schedules

renal dosing

[no adjustment]

renal impairment: no adjustment

HD/PD: no adjustment; no supplement

hepatic dosing

[no adjustment]